Back to results
US 2003/0212015 A1Published application
Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
OwnerRobert Taminventor
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerRobert Taminventor
Estimating the term…
Ribavirin is employed in a manner which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin is used to suppress Type 2-mediated T cell responses and promote Type 1-mediated T cell response. Thus, instead of administering Ribavirin in its well-recognized role as an anti-viral agent, Ribavirin is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection.
A method of modulating Type 1 and Type 2 response in activated T cells of a human patient comprising administering ribavirin to the T cells in a dosage which promotes the Type 1 response and suppresses the Type 2 response.
A method of treating a patient having a disease which includes a viral component and a non-viral component, the non-viral component being characterized by reduced Type 1 levels and increased Type 2 levels in activated T-lymphocytes, comprising administering ribavirin to the patient under a protocol sufficient to promote the Type 1 response and suppress the Type 2 response.
A method of inhibiting a virus by growing a virus in an environment having lymphocytes which produce Type 1 and Type 2 cytokine responses, and adding ribavirin to the environment in a concentration which increases the Type 1 response and suppresses the Type 2 response.
Dependencies are inferred from the claim text.